针对巨细胞病毒抗体（CMV-Ab）阴性的肾移植受者，独家使用CMV-Ab阴性供体的四年经验。
Four-year experience with exclusive use of cytomegalovirus antibody (CMV-Ab)-negative donors for CMV-Ab-negative kidney recipients.
作者信息
Ackermann J R, LeFor W M, Weinstein S, Kahana L, Shires D L, Tardif G, Baxter J
机构信息
Department of Surgery, University of South Florida, Tampa.
出版信息
Transplant Proc. 1988 Feb;20(1 Suppl 1):469-71.
Because of unacceptable CMV related morbidity, mortality, and graft loss, we adopted a policy that (-) patients would receive renal allografts only from (-) donors. This policy has resulted in a significant decrease in (1) morbidity (10.6% v 1.7%, P less than .0001), (2) mortality (3.7%) v 0%, P = .002), and (3) graft loss (2.5% v 0%, P = .016). CMV-Ab-negative patients (1) constitute 26% of all patients tested (compared with 36% of all donors tested), (2) receive transplants at the same rate as (+) patients, (3) do not have a prolonged waiting time, and (4) received greater HLA-A, B, -DR mismatched kidneys (3.6 v 3.1, P less than .01).
由于与巨细胞病毒（CMV）相关的发病率、死亡率和移植物丢失率令人难以接受，我们采取了一项政策，即CMV抗体阴性（-）的患者仅接受来自CMV抗体阴性（-）供体的肾移植。这一政策已使以下情况显著减少：（1）发病率（10.6%对1.7%，P<0.0001），（2）死亡率（3.7%对0%，P = 0.002），以及（3）移植物丢失率（2.5%对0%，P = 0.016）。CMV抗体阴性患者：（1）占所有检测患者的26%（相比之下，占所有检测供体的36%），（2）接受移植的比例与CMV抗体阳性（+）患者相同，（3）等待时间未延长，且（4）接受了更多HLA - A、B、 - DR错配的肾脏（3.6对3.1，P<0.01）。
Zotero 插件